The Latest Cardiac and Vascular News
After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. FLAGSTAFF, Ariz., Jan. 19, 2022 /PRNewswire/ — W. L. Gore & Associates (Gore) today announced that the GORE® CARDIOFORM Septal Occluder has achieved 10 years of clinical use, treating patients through clinical […]
Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization by adding radiopaque markers 25 years of continued innovation PUTZBRUNN, Germany, Sept. 22, 2021 /PRNewswire/ — As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the EMEA launch of the […]
FLAGSTAFF, Ariz., March 30, 2021 /PRNewswire/ — Today, W. L. Gore & Associates, Inc. (Gore) announces the first use of the FDA approved GORE® EXCLUDER® Conformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials. Cases were successfully performed by Robert Rhee, M.D. with Mahmoud Almadani, M.D., in Brooklyn, New York and by Gustavo Oderich, M.D. with Naveed Saqib, M.D., in Houston, Texas. The GORE EXCLUDER Conformable AAA Endoprosthesis, which […]
Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization under fluoroscopy FLAGSTAFF, Ariz., Sept. 22, 2020 /PRNewswire/ — As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the U.S. launch of the lower profile, large diameter GORE® VIABAHN® Endoprosthesis. Gore previously received approval […]
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) has completed enrollment for the pivotal phase of the Gore ASSURED Clinical Study. This investigational device exemption (IDE) trial is researching the new GORE®CARDIOFORM ASD Occluder for the interventional closure of Atrial Septal Defects (ASDs), sized 8 to 35 mm. The GORE®CARDIOFORM ASD Occluder is designed […]
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) today announced the first implant in conjunction with the Gore ARISE Study of the GORE® Ascending Stent Graft, an investigational device and the only endovascular stent graft specifically designed to treat Type A dissections of the ascending aorta. The successful procedure took place on August 14, 2018 at […]
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) announced FDA 510(k) clearance, approval from the Japanese Ministry of Health, Labour, and Welfare, and receipt of CE Mark for the innovative GORE® Molding & Occlusion Balloon, a compliant polyurethane balloon catheter designed in close collaboration with clinicians to assist in the expansion of self-expanding stent grafts or […]
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) today announced the first patient implant of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System after being included on the Australian Register of Therapeutic Goods last month in Australia. The first implants were performed by Professor Ian Spark at Flinders Medical Centre, Adelaide, […]
FLAGSTAFF, Ariz., April 3, 2018 /PRNewswire/ — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial […]
Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone Share: Twitter Linked In Source W. L. Gore Press Release FLAGSTAFF, Ariz. (May 16, 2017) – W. L. Gore & Associates, Inc. (Gore) announces positive results from its REDUCE Study assessing closure of […]
